comparemela.com

Latest Breaking News On - Functional outcomes - Page 9 : comparemela.com

Bacopa monnieri extract linked to multiple mental wellbeing perks

Biophytis Announces Temporary Trading Halt of its Ordinary Shares and Share Warrants on Euronext Growth

PARIS and CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) Biophytis (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, announces today that trading of its ordinary shares and share warrants on Euronext Growth will be temporarily halted at the Company’s request from the opening of the market at 9 a.m. CET in the context of its initial public offering on the Nasdaq Capital Market in order to allow for the confirmation of allocations to investors and for the commencement of trading of the Company’s American Depositary Shares (ADSs) on the Nasdaq Capital Market. This trading halt will remain effective until a new communication is released by

ATEC Continues to Advance Clinical Prowess with Renewed Agreement to Acquire EOS Imaging

Share: Accelerates revenue growth through Facilitates future global expansion via EOS established infrastructure Leverages the portfolio adoption driven by SafeOp with significant incremental opportunities to monetize clinical information Hosting webcast for investors December 17 at 6:00 A.M. PT CARLSBAD, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) Alphatec Holdings, Inc. ( ATEC or the Company ) (NASDAQ:ATEC), a medical device company dedicated to revolutionizing the approach to spine surgery, announced today that it has entered into an agreement to acquire EOS imaging, SA, for a purchase price of $79.7 million, plus the retirement debt of $37.2 million, in an all-cash transaction. SafeOp has substantiated the value of clinically actionable information by accelerating product adoption across our portfolio, said Pat Miles, Chairman and Chief Executive Officer. Our original investment thesis for EOS as a solution to better inform surgery never changed. With this transactio

Sio Gene Therapies Announces Positive Six-Month Follow-Up Data from Low-Dose Cohort of Phase

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Sio Gene Therapies Announces Positive Six-Month Follow-Up Data from Low-Dose Cohort of Phase . Sio Gene TherapiesDecember 15, 2020 GMT -  Generally well-tolerated with a favorable safety profile in five patients -  Serum beta-galactosidase enzyme activity increased in all patients at all timepoints between Day 7 and Month 6, representing an approximate doubling in enzyme activity after gene transfer -  At Month 6, enzyme activity restored to 23-57% (mean: 38%) of normal reference levels -  All five children demonstrated signs of clinical disease stability as assessed by Vineland-3 Growth Scale Value, Upright and Floor Mobility, and Clinical Global Impression (CGI) scales

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.